Search - tctmd.com

Displaying 181 - 200 of 352

Sort: Relevancy | Date

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

October 14, 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

News Conference News HFSA 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

October 12, 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

October 09, 2020

More HF Readmissions Among Black People From Deprived Neighborhoods

News Conference News HFSA 2020

More HF Readmissions Among Black People From Deprived Neighborhoods

October 06, 2020

Blood Pressure Insights in COVID-19: Watch for Drops and RAAS Red Flags

News Conference News

Blood Pressure Insights in COVID-19: Watch for Drops and RAAS Red Flags

September 10, 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

September 03, 2020

Novel Ultrasound Therapy Shows Promise for Patients Unfit for TAVR, SAVR

News Conference News EuroPCR 2020

Novel Ultrasound Therapy Shows Promise for Patients Unfit for TAVR, SAVR

July 01, 2020

Skipping Predilatation in Low-risk TAVR Patients Does Not Mar Outcomes

News Conference News TVT 2020

Skipping Predilatation in Low-risk TAVR Patients Does Not Mar Outcomes

June 19, 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

April 07, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

Survival Benefit Shown for Radial Artery Grafting in CABG

News Conference News ACC 2020

Survival Benefit Shown for Radial Artery Grafting in CABG

March 30, 2020

UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality

News Conference News ACC 2020

UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality

March 29, 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

March 28, 2020

Hypertension-Related CV Deaths Surging Across the US

News Conference News ACC 2020

Hypertension-Related CV Deaths Surging Across the US

March 24, 2020

Retrospective Analysis Isolates Predictors of Late Pacemaker Need Post-TAVR

News Conference News CRT 2020

Retrospective Analysis Isolates Predictors of Late Pacemaker Need Post-TAVR

March 06, 2020

Long-term Survival Data Promising for Carillon Repair Device in Functional MR

News Conference News CRT 2020

Long-term Survival Data Promising for Carillon Repair Device in Functional MR

March 03, 2020

AKI After TAVR Is Decreasing, but More Efforts Needed to Prevent Stage 3

News Conference News CRT 2020

AKI After TAVR Is Decreasing, but More Efforts Needed to Prevent Stage 3

February 27, 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

February 25, 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

News Conference News CRT 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

February 24, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.